Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. News
Altamira Therapeutics Ltd. Quantitative Score
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Altamira Therapeutics Ltd. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Altamira Therapeutics Ltd. Financials
Table Compare
Compare CYTO metrics with: | |||
|---|---|---|---|
Earnings & Growth | CYTO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CYTO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CYTO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CYTO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Altamira Therapeutics Ltd. Income
Altamira Therapeutics Ltd. Balance Sheet
Altamira Therapeutics Ltd. Cash Flow
Altamira Therapeutics Ltd. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Altamira Therapeutics Ltd. Executives
| Name | Role |
|---|---|
| Dr. Thomas Meyer Ph.D. | Founder, President, Chairman, Chief Executive Officer & MD |
| Mr. Marcel Gremaud CPA | Chief Financial Officer |
| Dr. Covadonga Paneda | Chief Operating Officer |
| Dr. Samuel A. Wickline M.D. | Chief Scientific Adviser |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Thomas Meyer Ph.D. | Founder, President, Chairman, Chief Executive Officer & MD | 1968 | 613.29K | |
| Mr. Marcel Gremaud CPA | Chief Financial Officer | Male | 1958 | -- |
| Dr. Covadonga Paneda | Chief Operating Officer | 1974 | -- | |
| Dr. Samuel A. Wickline M.D. | Chief Scientific Adviser | 1953 | -- |
Altamira Therapeutics Ltd. Insider Trades
| Date | 8 May |
| Name | CARTER STEPHEN |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 10000 |
| Date | 8 May |
| Name | LOKAY KEVIN G |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 185439 |
| Date | 8 May |
| Name | LOKAY KEVIN G |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 100000 |
| Date | 8 May |
| Name | MOLLICA JOSEPH A |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 10000 |
| Date | 13 Nov |
| Name | LOKAY KEVIN G |
| Role | CEO, President & Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 500000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 8 May | CARTER STEPHEN | Director | Disposed | D-Return | 10000 |
| 8 May | LOKAY KEVIN G | Director | Disposed | D-Return | 185439 |
| 8 May | LOKAY KEVIN G | Director | Disposed | D-Return | 100000 |
| 8 May | MOLLICA JOSEPH A | Director | Disposed | D-Return | 10000 |
| 13 Nov | LOKAY KEVIN G | CEO, President & Director | Acquired | A-Award | 500000 |